The original version of this article unfortunately contained an error. An incorrect phrase was included. The correct sentence should read as given below.
Section ''Introduction'', first paragraph, lines 43-52, the second last sentence of the paragraph should read: ''Actually, we have been reported the discovery of highly selective and potent new-class non-peptide NOP receptor full agonists in the distinct two series of drug-design, synthesis and structure-activity relationship (SAR) studies by Hayashi et al. (2009a Hayashi et al. ( , b, 2010 , respectively, thus, HPCOM as a systemically potent new-class analgesic for the treatment of neuropathic pain, and MCOPPB as an orally potent new-class anxiolytic, with robust metabolic stabilities and little potential risks of human ether-a-go-go related gene (hERG) ion channel binding issues, respectively.''
The online version of the original article can be found under doi:10.1007/s00044-013-0595-3.
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